Drug Name (select from list of drugs shown) Tysabri (natalizumab) Quantity Frequency Strength Route of Administration

Similar documents
Prior Authorization Form

Clinical Policy: Natalizumab (Tysabri) Reference Number: CP.PHAR.259

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Teriflunomide (Aubagio) Reference Number: CP.PHAR.262 Effective Date: Last Review Date: 05.18

See Important Reminder at the end of this policy for important regulatory and legal information.

See Important Reminder at the end of this policy for important regulatory and legal information.

Clinical Policy: Ocrelizumab (Ocrevus) Reference Number: CP.PHAR.335 Effective Date: Last Review Date: 05.18

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Medication Prior Authorization Form

See Important Reminder at the end of this policy for important regulatory and legal information.

Approved by: Pharmacy and Therapeutics Quality Management Subcommittee Effective Date: Department of Origin: Pharmacy. Date approved: 06/21/17

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

Approval of a drug under this criteria document does not ensure full coverage of the drug.

See Important Reminder at the end of this policy for important regulatory and legal information.

CIBMTR Center Number: CIBMTR Recipient ID: RETIRED. EBMT Center Identification Code (CIC): Today s Date:

Approval of a drug under this criteria document does not ensure full coverage of the drug.

Form 2043 R3.0: Multiple Sclerosis Pre-HSCT data

Current Trends in Specialty Pharmacy Management. priorityhealth.com

Multiple Sclerosis Agents

National Horizon Scanning Centre. Cladribine (Movectro) for multiple sclerosis; relapsing-remitting. April 2008

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

S.E.A.R.C.H. SM Patient Workbook

COMPOUND MEDICATION NON-FORMULARY (QUALIFIED HEALTH PLANS)

Lemtrada (alemtuzumab)

Aubagio (teriflunomide tablets) Policy Number: Last Review: 07/2017 Origination: 07/2014 Next Review: 07/2018

LEMTRADA (ALEMTUZUMAB)

Tysedmus, a Registry of Multiple Sclerosis patients exposed to Natalizumab

Clinical Policy: Multiple Sclerosis Reference Number: CP.CPA.206 Effective Date: Last Review Date: Line of Business: Commercial

LEMTRADA (ALEMTUZUMAB)

Multiple Sclerosis Agents Drug Class Prior Authorization Protocol

2006 Focus on Specialty Pharmacy

Prior Authorization Criteria Hemophilia/Blood Factor Products

NB Drug Plans Formulary Update

Introducing MN-166 Multiple Sclerosis. July 9, 2008

IR Thematic Call on Multiple Sclerosis

REFERENCE CODE GDHC221CFR PUBLICATION DATE FEBRUARY 2014 ULCERATIVE COLITIS - CANADA DRUG FORECAST AND MARKET ANALYSIS TO 2022

Multiple sclerosis (MS) is a chronic, unpredictable

Integrin Alpha 4 (CD49 Antigen Like Family Member D or VLA4 Subunit Alpha or CD49d or ITGA4) - Pipeline Review, H2 2016

Antibody therapy of multiple sclerosis Prof. Alastair Compston Dr. Alasdair Coles

This Coverage Policy applies to Individual Health Insurance Marketplace benefit plans only.

Approval of a drug under this criteria document does not ensure full coverage of the drug.

This presentation was developed by the Government & Industry Affairs Committee of the Crohn s & Colitis Foundation of America

Outline. References. Marshall,1

REFERENCE CODE GDHC342DFR PUBLICAT ION DATE FEBRUARY 2014 ENTYVIO (ULCERATIVE COLITIS) - FORECAST AND MARKET ANALYSIS TO 2022

Helen C. Pervanas, Pharm.D. Associate Professor of Pharmacy Practice MCPHS Worcester/Manchester

Natalizumab (Tysabri) Humanized, MAb Against α 4 subunit of α 4 β 1 Integrin. Multiple Sclerosis Treatment Update

REFERENCE CODE GDHC218CFR PUBLICAT ION DATE FEBRUARY 2014 ULCERATIVE COLITIS - US DRUG FORECAST AND MARKET ANALYSIS TO 2022

Request for Prior Authorization for Synagis (palivizumab) Website Form Submit request via: Fax

Opexa Therapeutics, Inc.

A blood sample will be collected annually for up to 2 years for JCV antibody testing.

Common Drug Review Pharmacoeconomic Review Report

Beta interferon and glatiramer acetate for treating multiple sclerosis (review of TA32)

MS Injectable Drugs

Credit Suisse Healthcare Conference

There are currently 4 US Food and Drug

Specialty medicine: Pearls from the PBMI conference, Scottsdale, Arizona Dr. Elsa Badenhorst

Clinical Policy: Thalidomide (Thalomid) Reference Number: ERX.SPMN.95

Update on New MS Therapeutics

Credit Suisse 7 th Annual European Large Cap Pharmaceutical Conference. November 6, 2007

REFERENCE CODE GDHC209CFR PUBLICAT ION DATE J ANU ARY 2014 CROHN S DISEASE 5EU DRUG FORECAST AND MARKET ANALYSIS TO 2022

REFERENCE CODE GDHC348DFR PUBLICAT ION DATE FEBRUARY 2014 APRISO (ULCERATIVE COLITIS) - FORECAST AND MARKET ANALYSIS TO 2022

The MS Disease- Modifying Medications. General information

EXANE Conference. Jérôme Contamine, Executive Vice President, Chief Financial Officer. Paris June 13, 2017

REFERENCE CODE GDHC354DFR PUBLICAT ION DATE FEBRUARY 2014 UCERIS (ULCERATIVE COLITIS) - FORECAST AND MARKET ANALYSIS TO 2022

Dirucotide (MBP8298) for the treatment of multiple sclerosis

UNCLASSIFIED J-CODE CODING AND BILLING US/ULT-PNH/0002

See Important Reminder at the end of this policy for important regulatory and legal information.

FORMULARY MANAGEMENT ABSTRACT

Multiple Sclerosis: KOL Insight 2016

SESSION VI THE CHALLENGE OF NEW TREATMENTS THE PHARMA INDUSTRY

See Important Reminder at the end of this policy for important regulatory and legal information.

OCREVUS Start Form. Instructions for Patients. Instructions for Health Care Providers

REFERENCE CODE GDHC347DFR PUBLICAT ION DATE FEBRUARY 2014 SIMPONI (ULCERATIVE COLITIS) - FORECAST AND MARKET ANALYSIS TO 2022

Future Directions in IBD: Treatments & Approaches

First Name Last Name Patient Gender. Patient DOB Patient Phone # Alternative Phone # City State Zip code. Prescriber Name Contact Name Contact Phone #

Disease-Modifying Therapies for Relapsing- Remitting and Primary-Progressive Multiple Sclerosis: Effectiveness and Value

Treatment: Nutrition and Medication

Cladribine. Spirella Building, Letchworth, SG6 4ET reg charity no

SECURITIES AND EXCHANGE COMMISSION Washington, D.C FORM 8-K CURRENT REPORT

Biologics in IBD: Optimizing Therapies and Emerging Agents

REFCTRI/2010/ CTRI Website URL -

Biogen Idec Q Earnings Conference Call and Webcast. April 23 rd 2008

VALIDATION ERRORS. No 6 Service not selected A Service must be selected on the Form. No 7 Billing Provider must have a Tax ID

Measuring the Potential Health Impact of Personalized Medicine: Evidence from Multiple Sclerosis Treatments. Kristopher J. Hult.

NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal

BIOLOGIC AND BIOSIMILAR MEDICATIONS

Health. bulletin. Important: Formulary Drug Removals DECEMBER 2017

90% 80% 70% 60% 50% 40% 30% 20% 10% 0%

Multiple Sclerosis International Federation December 2018

National MS Society Information Sourcebook

Technology appraisal guidance Published: 27 August 2014 nice.org.uk/guidance/ta320

FDA Just Approved Some Highly Anticipated Specialty Drugs; Payers Must Prepare Now

Biogen Idec Q Earnings Conference Call and Webcast. February 6 th 2008

The legally binding text is the original French version TRANSPARENCY COMMITTEE OPINION. 6 April 2011

Biogen Idec Q Earnings Conference Call and Webcast. July 22 nd 2008

The last decade has witnessed the introduction of a series of disease-modifying agents as

RedHill Biopharma Ltd. (NASDAQ/ TASE: RDHL)

INVESTIGATIONAL DEVICES & DRUGS. What is an IRB to do?

Transcription:

04/30/2014 Prior Authorization Form MERCY CARE PLAN (MEDICAID) Tysabri (Medicaid) This fax machine is located in a secure location as required by HIPAA regulations. Complete/review information, sign and date. Fax signed forms to Mercy Care Plan at 1-800-854-7614. Please contact Mercy Care Plan at 1-800-624-3879 with questions regarding the prior authorization process. When conditions are met, we will authorize the coverage of Tysabri (Medicaid). Please note that all authorization requests will be reviewed as the AB rated generic (when available) unless states otherwise Drug Name (select from list of drugs shown) Tysabri (natalizumab) Quantity Frequency Strength Route of Administration Patient Information Patient Name: Patient ID: Patient Group No.: Patient DOB: Patient Phone: Prescribing Physician Expected Length of Therapy

Physician Name: Physician Phone: Physician Fax: Physician Address: City, State, Zip: Diagnosis: ICD Code: Comments: Please circle the appropriate answer for each question. 1. Has Mercy Care Plan authorized this medication in the past for this patient (i.e., previous authorization is on file under Mercy Care Plan)? [If no, skip to question 7.] 2. Has the patient received Tysabri therapy for less than 6 months? [If no, skip to question 4.] 3. Is there documentation supporting a response to therapy? 4. Has the patient received between 6 months and 2 years of Tysabri therapy? Document start date of

treatment: 5. Has the patient received Tysabri therapy for 2 years or more? [If yes, no further questions] 6. Is there documentation supporting patient meets one of the following: Multiple sclerosis: patient is responding to therapy \ Crohn s disease: patient has been able to taper off of corticosteroid therapy 7. Is the patient 18 years of age or older? 8. Does the patient meet both of the following criteria? Tysabri will be used as monotherapy, AND \ Patient will not be taking antineoplastic, immunosuppressive, or immunomodulating agents (e.g., azathioprine, 6-mercaptopurine, cyclosporine, methotrexate, TNF-inhibitors). 9. Does the patient have a diagnosis of relapsing-remitting multiple sclerosis (RRMS) [If no, skip to question 12.] 10. Is Tysabri prescribed by a neurologist?

11. Has the patient failed a compliant regimen of at least two formulary medications (e.g., Avonex, Rebif, Betaseron, Extavia, Copaxone)? Please document medications tried: 12. Does the patient have a diagnosis of Crohn s disease (CD)? 13. Is Tysabri prescribed by a gastroenterologist? 14. Does the patient meet ONE of the (if patient has corticosteroids, list contraindication/intolerance): Trial and failure of a compliant regimen of oral corticosteroids (for moderate to severe CD) or intravenous corticosteroids (for severe and fulminant CD) for one month OR \ Documented contraindication or intolerance to PO or IV corticosteroids 15. Does the patient meet ONE of the

(if patient has azathioprine or mercaptopurine, list contraindication/intolerance): Trial and failure of a compliant regimen of azathioprine or mercaptopurine for three consecutive months OR \ Documented contraindication or intolerance to azathioprine or mercaptopurine 16. Does the patient meet one of the (if patient has Humira or Remicade, list contraindication/intolerance): Trial and failure of a compliant regimen of Humira or Remicade for three consecutive months OR \ Documented contraindication or intolerance to Humira or Remicade I affirm that the information given on this form is true and accurate as of this date. Prescriber (Or Authorized) Signature and Date